about
A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancersPerturbations at the ribosomal genes loci are at the centre of cellular dysfunction and human diseaseInhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signalingInhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell populationA novel role for the Pol I transcription factor UBTF in maintaining genome stability through the regulation of highly transcribed Pol II genes.Widespread FRA1-dependent control of mesenchymal transdifferentiation programs in colorectal cancer cells.Genome wide mapping of UBF binding-sites in mouse and human cell lines.Inhibition of glycogen synthase kinase-3 in androgen-responsive prostate cancer cell lines: are GSK inhibitors therapeutically useful?Immunophenotypic, cytogenetic, and mutational characterization of cell lines derived from myelodysplastic syndrome patients after progression to acute myeloid leukemia.PR55α-containing protein phosphatase 2A complexes promote cancer cell migration and invasion through regulation of AP-1 transcriptional activity.A 19S proteasomal subunit cooperates with an ERK MAPK-regulated degron to regulate accumulation of Fra-1 in tumour cells.Transcriptional profiles for distinct aggregation states of mutant Huntingtin exon 1 protein unmask new Huntington's disease pathways.A novel mouse model of atherosclerotic plaque instability for drug testing and mechanistic/therapeutic discoveries using gene and microRNA expression profiling.Polycomb protein RING1A limits hematopoietic differentiation in myelodysplastic syndromes.Epigenetic-Transcriptional Regulation of Fatty Acid Metabolism and Its Alterations in LeukaemiaChanges in long-range rDNA-genomic interactions associate with altered RNA polymerase II gene programs during malignant transformationA functional genetic screen defines the AKT-induced senescence signaling network
P50
Q26743743-0E0E74DF-C9E2-4A08-82D4-25624990C23CQ27005780-F26BB825-1373-4356-B016-1F02039534B6Q28468631-8478898B-484D-4715-997B-92024E91743DQ33731216-9A3F76AE-FE2B-429D-B646-B62DA7393317Q34042569-62F9D83E-381A-492D-92A6-566F0DDEFF43Q35128358-3E415168-38FC-4197-846F-5B853205A999Q35814075-7848A855-5FF0-4066-ACBA-61BE083BCE0DQ36661732-0A80233A-6FE0-4003-8EFC-E7F94519AD47Q38740563-B2F603F0-A9B3-4B96-AF2C-1FD829C0D453Q39015110-B535AC61-ADD9-44AB-B1B9-0BD30AC4C7EBQ39483038-7784D66B-8527-4891-984D-E9B807231D77Q45303343-89DE8BCD-D63F-4E7C-A042-D13492720374Q45339629-3255BECB-0D87-4B47-9FA0-16D274538B3EQ49235235-AD3F25F6-9035-417C-AC93-A0629EDCFE67Q57492375-238DB8F6-C644-4E2C-8ECB-2EA245A0E3DEQ61443253-1CCAA046-C4E1-4D9C-979B-473F0008CE46Q91723465-B42336CE-DA50-44CA-8BF1-513BF1A2EDE0
P50
description
onderzoeker
@nl
researcher, ORCID id # 0000-0002-4667-3468
@en
name
Jeannine Diesch
@ast
Jeannine Diesch
@en
Jeannine Diesch
@es
Jeannine Diesch
@nl
type
label
Jeannine Diesch
@ast
Jeannine Diesch
@en
Jeannine Diesch
@es
Jeannine Diesch
@nl
prefLabel
Jeannine Diesch
@ast
Jeannine Diesch
@en
Jeannine Diesch
@es
Jeannine Diesch
@nl
P106
P31
P496
0000-0002-4667-3468